It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Multiple sclerosis (MS) is an autoimmune disease characterized by multiple lesions in the brain and spinal cord. We used RNA sequencing to identify microbial sequences and characterize human gene expression patterns in 30 human brain biopsy specimens. RNAs which aligned to known microbial taxa, were significantly enriched in 10 of 12 primary demyelination (MS) brain specimens compared to a group of 15 epilepsy controls, leading to a list of 29 MS microbial candidate genera from 11 different phyla. Most of the candidate MS microbes are anaerobic bacteria. While there were some shared candidates, each of the 10 MS samples with significant microbial RNA enrichment had a distinct set microbial candidates. The fraction of microbial sequencing reads was greater for the MS group (128.8 PPM) compared to the controls (77.4 PPM, p = 0.016). Bacterial peptidoglycan was demonstrated in brain tissue sections from several MS subjects. Human gene expression analysis showed increased expression of inflammation-related pathways in the MS group. This data shows that demyelinating brain lesions are associated with the presence of microbial RNA sequences and bacterial antigen. This suggests that MS is triggered by the presence of a diverse set of microbes within a lesion.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 University of Utah School of Medicine, Department of Internal Medicine, Division of Infectious Diseases, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
2 University of Utah School of Medicine, Department of Pediatrics, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
3 University of Utah School of Medicine, Department of Neurology, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
4 University of Utah School of Medicine, Department of Pathology, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096)
5 University of Utah School of Medicine, Department of Pathology, Salt Lake City, USA (GRID:grid.223827.e) (ISNI:0000 0001 2193 0096); uBiota LLC, Salt Lake City, USA (GRID:grid.223827.e)